Altimmune, Inc (ALT) Fair Value & Analysis
Healthcare · US · Market cap $514M
Altimmune, Inc
ALT · US
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 8 days ago
Share price +9.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $2.39 – $5.69 · fair‑value band $3.90 – $6.50 · the $2.91 price screens below the $5.20 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Altimmune, Inc (ALT) currently trades at $2.91, while our model-based Fair Value estimate is $5.20 — implying the stock looks roughly 78.7% undervalued today. We read business quality at 26/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $36.0K. It earns a return on equity of -42.8%. The balance sheet holds a net cash position of $8.1M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Altimmune, Inc reported revenue of $41.0K in FY2025 versus $4.4M in FY2021, a compound −68.9%/yr. Reported net income was −$88.1M in FY2025.
Is ALT fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 4,803 MXN | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Altimmune, Inc (ALT) undervalued?
What is the fair value of ALT?
What is the quality score of ALT?
What is the revenue of Altimmune, Inc (ALT)?
What is the net profit margin of ALT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.